American Healthcare REIT, Inc.

NYSE:AHR Stock Report

Market Cap: US$4.5b

American Healthcare REIT Valuation

Is AHR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AHR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: AHR ($28.58) is trading below our estimate of fair value ($40.8)

Significantly Below Fair Value: AHR is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AHR?

Key metric: As AHR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AHR. This is calculated by dividing AHR's market cap by their current revenue.
What is AHR's PS Ratio?
PS Ratio2.2x
SalesUS$2.01b
Market CapUS$4.46b

Price to Sales Ratio vs Peers

How does AHR's PS Ratio compare to its peers?

The above table shows the PS ratio for AHR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.8x
SBRA Sabra Health Care REIT
6.4x5.8%US$4.4b
CTRE CareTrust REIT
21.1x17.0%US$5.7b
NHI National Health Investors
10.7x13.7%US$3.5b
LTC LTC Properties
8.9x-2.4%US$1.8b
AHR American Healthcare REIT
2.2x9.7%US$4.5b

Price-To-Sales vs Peers: AHR is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (11.8x).


Price to Sales Ratio vs Industry

How does AHR's PS Ratio compare vs other companies in the US Health Care REITs Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
DHC Diversified Healthcare Trust
0.4x5.3%US$581.47m
HLTC National Healthcare Properties
0.1xn/aUS$52.72m
GBCS Selectis Health
0.1xn/aUS$5.21m
No more companies available in this PS range
AHR 2.2xIndustry Avg. 5.6xNo. of Companies3PS02.85.68.411.214+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AHR is good value based on its Price-To-Sales Ratio (2.2x) compared to the US Health Care REITs industry average (5.6x).


Price to Sales Ratio vs Fair Ratio

What is AHR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AHR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.2x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: AHR is expensive based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AHR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$28.58
US$29.00
+1.5%
12.6%US$36.00US$22.00n/a8
Nov ’25US$26.17
US$27.63
+5.6%
9.0%US$31.00US$22.00n/a8
Oct ’25US$25.38
US$27.00
+6.4%
11.6%US$31.00US$22.00n/a8
Sep ’25US$20.93
US$19.57
-6.5%
21.5%US$27.00US$14.00n/a7
Aug ’25US$16.07
US$15.71
-2.2%
6.6%US$17.00US$14.00n/a7
Jul ’25US$14.76
US$16.00
+8.4%
7.7%US$18.00US$14.00n/a8
Jun ’25US$14.66
US$15.88
+8.3%
7.3%US$18.00US$14.00n/a8
May ’25US$13.88
US$15.75
+13.5%
7.6%US$18.00US$14.00n/a8
Apr ’25US$14.49
US$15.88
+9.6%
8.0%US$18.00US$14.00n/a8

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies